At1g73400 Antibody
Description
General Antibody Structure and Function
Antibodies are Y-shaped proteins produced by B cells that recognize and neutralize foreign antigens. They consist of two heavy chains and two light chains, with variable regions (CDRs) responsible for antigen binding .
Monoclonal Antibody Applications
Monoclonal antibodies (mAbs) are widely used in diagnostics and therapeutics. For example:
-
Cancer: Trastuzumab targets HER2/neu receptors, while rituximab binds CD20 on B cells .
-
Autoimmune diseases: Adalimumab and infliximab inhibit TNF-α .
-
Infectious diseases: Sotrovimab neutralizes SARS-CoV-2 spike proteins .
| Therapeutic Target | Antibody Example | Mechanism |
|---|---|---|
| HER2/neu receptor | Trastuzumab | Blocks signaling pathways |
| CD20 | Rituximab | Depletes B cells via Fc-mediated cytotoxicity |
| TNF-α | Adalimumab | Inhibits pro-inflammatory cytokine activity |
Antibody Engineering and Stability
IgG subclass selection (e.g., IgG1, IgG2, IgG4) impacts manufacturability and stability. IgG1 is prone to hinge fragmentation, while IgG4 exhibits reduced FcγR binding .
Anti-Osteoprotegerin Antibody (ab73400)
Though not At1g73400, ab73400 is a rabbit polyclonal antibody targeting human osteoprotegerin. It is validated for Western blot (WB), immunohistochemistry (IHC), and immunofluorescence (IF), with observed bands at ~105 kDa and 48 kDa .
Limitations in Current Data
-
No sources mention "At1g73400 Antibody" or correlate with Arabidopsis thaliana gene models (e.g., At1g73400).
-
The identifier "ab73400" refers to an osteoprotegerin antibody, distinct from the queried compound.
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Target Background
KEGG: ath:AT1G73400
STRING: 3702.AT1G73400.1
Q&A
The following FAQs address key considerations for researchers working with the At1g73400 antibody in academic contexts, synthesized from methodological frameworks in contemporary antibody research. While specific experimental data for At1g73400 is unavailable in current literature, these questions reflect best practices derived from analogous monoclonal antibody studies .
Advanced Research Questions
What computational strategies optimize At1g73400-抗原 binding affinity?
Employ residue-level energy decomposition models like ABDPO to:
How to analyze antibody-antigen complex stability under physiological conditions?
-
Use sedimentation velocity analytical ultracentrifugation (SV-AUC) to:
What structural biology approaches determine At1g73400's paratope-epitope landscape?
-
Cryo-EM reconstruction at ≤3.5Å resolution for global binding orientation
-
Hydrogen-deuterium exchange MS to map dynamic interaction regions
-
Alanine scanning mutagenesis of CDR residues (H3, L1 domains)
Comparative Methodological Analysis
How to evaluate genetic variability impact on antibody performance?
| Variability Source | Mitigation Strategy | Assay Type |
|---|---|---|
| Allelic diversity | Test 3+ Arabidopsis ecotypes | ELISA |
| Alternative splicing | Isoform-specific peptide arrays | Microarray |
| Post-translational modification | Glycosidase treatment | Western blot |
What statistical frameworks resolve batch-to-batch variability in antibody production?
-
Apply mixed-effects model:
Where = batch effect, = experimental condition
-
Require ≤15% CV across 3 independent lots by SDS-PAGE densitometry
Translational Research Considerations
How to adapt At1g73400 antibody for in vivo tracking studies?
-
Fc engineering: Introduce N297A mutation to prevent ADE while maintaining half-life
-
Fluorophore conjugation: Optimize dye:antibody ratio (4-6:1) via hydrophobic interaction chromatography
-
Validation metric: Signal:background ratio >8 in root apical meristem sections
What systems biology approaches contextualize At1g73400 expression data?
-
Build protein interaction networks using:
-
STRING database (confidence >0.7)
-
Co-expression modules from ATTED-II
-
Machine learning prediction of functional partners
-
